Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim) compared with placebo on vasomotor symptoms in highly symptomatic menopausal patients

Wulf H. Utian, Kenneth A. Burry, David F. Archer, John C. Gallagher, Robert L. Boyett, Martine P. Guy, Gilles J. Tachon, Harbajan K. Chadha-Boreham, Agnès A. Bouvet

Research output: Contribution to journalArticle

104 Scopus citations


OBJECTIVE: Our purpose was to evaluate the efficacy and safety of 3 dosages of Esclim, delivering 0.025 mg, 0.050 mg, or 0.100 mg 17β-estradiol per 24 hours, in the treatment of moderate to severe vasomotor symptoms. STUDY DESIGN: In this double-blind, placebo-controlled, parallel-group, multicenter trial, 196 highly symptomatic menopausal women received 12 weeks of continuous unopposed treatment with 1 of the 3 dosages of Esclim or a matching placebo patch. RESULTS: The reduction in frequency of moderate to severe vasomotor symptoms was statistically significant compared with placebo (P

Original languageEnglish (US)
Pages (from-to)71-79
Number of pages9
JournalAmerican Journal of Obstetrics and Gynecology
Issue number1
StatePublished - Jan 1 1999


All Science Journal Classification (ASJC) codes

  • Obstetrics and Gynecology

Cite this